EBV-specific cytotoxic T lymphocytes protect against human EBV-associated lymphoma in scid mice

被引：22

作者：

Buchsbaum, RJ

Fabry, JA

Lieberman, J

机构：

[1] TUFTS UNIV NEW ENGLAND MED CTR,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02111

[2] HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115

来源：

IMMUNOLOGY LETTERS | 1996年 / 52卷 / 2-3期

关键词：

Epstein-Barr virus (EBV); cytotoxic T lymphocyte (CTL); lymphoma; scid mice;

D O I：

10.1016/0165-2478(96)02602-8

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Scid mice develop human EBV-positive B cell tumors after injection with EBV-transformed human B cells or peripheral blood lymphocytes from EBV-seropositive donors. Injection of cytotoxic T cell (CTL) lines, selectively expanded in vitro to recognize autologous EBV-transformed B cells, protected mice against developing human lymphoproliferative disease. CTL protection required a single dose of polyethylene-glycol-conjugated IL2. Mice were not protected by CTL that did not specifically recognize EBV-transformed B cells or by mitogen-activated lymphocytes.

引用

页码：145 / 152

页数：8

共 50 条

[31] Generation of EBV-specific CTLs suitable for adoptive immunotherapy of EBV-associated lymphoproliferative disease following allogeneic transplantation
Hoffmann, T
Russell, C
Vindelov, L
APMIS, 2002, 110 (02) : 148 - 157
[32] In vivo behavior of genetically modified EBV-specific T lymphocytes.
Heslop, HE
Ng, CYK
Smith, CA
Li, C
Loftin, S
Krance, RA
Brenner, MK
Rooney, CM
BLOOD, 1995, 86 (10) : 2461 - 2461
[33] CGMP PRODUCTION OF CMV AND EBV-SPECIFIC T LYMPHOCYTES FOR ADOPTIVE TRANSFER
Codinach, M.
Blanco, M.
Lloret, M.
Ortega, I.
Reales, L.
Coca, M.
Torrents, S.
Doral, M.
Requena, M.
Vives, J.
Gimeno, R.
Diaz de Heredia, C.
Alonso, L.
Coll, R.
Garcia, J.
CYTOTHERAPY, 2016, 18 (06) : S60 - S60
[34] Autologous EBV-specific cytotoxix T lymphocytes for the treatment of EBV-related nasopharyngeal carcinoma.
Pedrazzoli, P
Comoli, P
Secondino, S
Basso, S
Schiavo, R
Schiavetto, I
Frasson, C
Locatelli, F
Maccario, R
Siena, S
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 168S - 168S
[35] Human cytotoxic T lymphocyte responses to Epstein-Barr virus (EBV) - Implications for immunotherapy of EBV-associated malignancies
Gavioli, R
MINERVA BIOTECNOLOGICA, 1999, 11 (01) : 1 - 6
[36] Administrations of Tumor-Specific Cytotoxic T Lymphocytes Engineered to Resist TGF-β to Patients with EBV-Associated Lymphomas
Bollard, Catherine M.
Dotti, Gianpietro
Gottschalk, Stephen
Liu, Enli
Sheehan, Andrea
Mims, Martha
Liu, Hao
Gee, Adrian P.
Brenner, Malcolm K.
Heslop, Helen E.
Rooney, Cliona M.
BLOOD, 2010, 116 (21) : 248 - 248
[37] DONOR T-CELLS TO TREAT EBV-ASSOCIATED LYMPHOMA
HESLOP, HE
BRENNER, MK
ROONEY, CM
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (10): : 679 - 680
[38] EBV-ASSOCIATED T-CELL LYMPHOMA OF CHILDHOOD WITH HEMOPHAGOCYTOSIS
Kozai, Landon
Holm-Kennedy, Robert
Shah, Parthav
CHEST, 2023, 164 (04) : 2943A - 2943A
[39] Autologous EBV-Specific T Cells (CMD-003): Early Results from a Multicenter, Multinational Phase 2 Trial for Treatment of EBV-Associated NK/T-Cell Lymphoma
Kim, Won Seog
Ardeshna, Kirit M.
Lin, Yi
Oki, Yasuhiro
Ruan, Jia
Jacobsen, Eric D.
Yoon, Dok Hyun
Suh, Cheolwon
Suarez, Felipe
Porcu, Pierluigi
Brammer, Jonathan E.
Radford, John
Budde, Lihua E.
Kim, Jin Seok
Salles, Gilles
Bollard, Catherine M.
Jaccard, Arnaud
Kang, Hye Jin
Inman, Shannon
Murray, Maryann
Gunter, Kurt C.
Lee, Daniel Y.
Rooney, Cliona M.
Heslop, Helen E.
BLOOD, 2017, 130
[40] EBV-related PTLD after kidney transplantation: Successful treatment with a tailored regimen including autologous EBV-specific cytotoxic T lymphocytes.
Comoli, P
Maccario, R
Valente, U
Labirio, M
Basile, G
Garaventa, A
Nocera, A
Perfumo, F
Locatelli, F
Ginevri, F
AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 250 - 251

← 1 2 3 4 5 →